CR20220566A - Compuestos y métodos para modular el corte y empalme - Google Patents
Compuestos y métodos para modular el corte y empalmeInfo
- Publication number
- CR20220566A CR20220566A CR20220566A CR20220566A CR20220566A CR 20220566 A CR20220566 A CR 20220566A CR 20220566 A CR20220566 A CR 20220566A CR 20220566 A CR20220566 A CR 20220566A CR 20220566 A CR20220566 A CR 20220566A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- compounds
- modulating splicing
- splicing
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Replacement Of Web Rolls (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007331P | 2020-04-08 | 2020-04-08 | |
| US202063044318P | 2020-06-25 | 2020-06-25 | |
| US202063072922P | 2020-08-31 | 2020-08-31 | |
| US202063126494P | 2020-12-16 | 2020-12-16 | |
| PCT/US2021/026481 WO2021207554A1 (en) | 2020-04-08 | 2021-04-08 | Compounds and methods for modulating splicing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220566A true CR20220566A (es) | 2023-01-23 |
Family
ID=75690721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220566A CR20220566A (es) | 2020-04-08 | 2021-04-08 | Compuestos y métodos para modular el corte y empalme |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230159496A1 (https=) |
| EP (1) | EP4132646A1 (https=) |
| JP (1) | JP2023520916A (https=) |
| KR (1) | KR20220167298A (https=) |
| CN (1) | CN115551593A (https=) |
| AU (1) | AU2021253587A1 (https=) |
| BR (1) | BR112022020423A2 (https=) |
| CA (1) | CA3174353A1 (https=) |
| CL (1) | CL2022002780A1 (https=) |
| CO (1) | CO2022015925A2 (https=) |
| CR (1) | CR20220566A (https=) |
| IL (1) | IL297137A (https=) |
| MX (1) | MX2022012678A (https=) |
| TW (1) | TWI912305B (https=) |
| WO (2) | WO2021207532A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN114126613A (zh) | 2019-02-05 | 2022-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| CN113661162A (zh) | 2019-02-06 | 2021-11-16 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| BR112022023025A2 (pt) | 2020-05-13 | 2023-03-28 | Chdi Foundation Inc | Moduladores de htt para tratar doença de huntington |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CA3233973A1 (en) * | 2021-10-13 | 2023-04-20 | Dominic Reynolds | Compounds and methods for modulating nucleic acid splicing |
| US12281116B2 (en) | 2021-11-17 | 2025-04-22 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| AU2022398247A1 (en) * | 2021-11-24 | 2024-06-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250326748A1 (en) * | 2022-01-05 | 2025-10-23 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| EP4724436A1 (en) * | 2023-06-12 | 2026-04-15 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CN120388720B (zh) * | 2024-09-18 | 2026-02-17 | 大连医科大学附属第二医院 | 基于uqcc2与mettl3的计算机辅助筛选药物的方法、系统和设备 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0309765A3 (en) * | 1987-09-30 | 1990-09-26 | Fisons Corporation | 1(2h)-phthalazinones as cytoprotective agents |
| AU761453B2 (en) * | 1999-03-17 | 2003-06-05 | Astrazeneca Ab | Amide derivatives |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| WO2009036144A1 (en) * | 2007-09-12 | 2009-03-19 | Wyeth | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| NZ598220A (en) * | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| DK2812004T3 (en) | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP2968340A4 (en) * | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
| MA41898A (fr) * | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| EP3353164B1 (en) * | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| CN107344931B (zh) * | 2016-05-06 | 2020-09-15 | 上海迪诺医药科技有限公司 | 苯并氮杂卓衍生物、其制备方法、药物组合物及应用 |
| US10913730B2 (en) * | 2016-10-10 | 2021-02-09 | Dong-A Socio Holdings Co., Ltd. | Heteroaryl compounds and their use as Mer inhibitors |
| EA201991309A1 (ru) | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| CA3045339A1 (en) * | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| CN108658990B (zh) * | 2017-03-31 | 2021-03-23 | 南京科技职业学院 | 一类新型咪唑并[1,5-a]吡嗪类布鲁顿激酶抑制剂 |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| KR20200057071A (ko) | 2017-09-25 | 2020-05-25 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물 |
| CN109721597B (zh) * | 2017-10-30 | 2021-05-14 | 上海迪诺医药科技有限公司 | 吡啶并氮杂卓衍生物、其药物组合物及应用 |
| EP3706747B1 (en) * | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3717471B1 (en) * | 2017-12-02 | 2022-01-05 | Galapagos NV | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CN112272666A (zh) | 2018-04-10 | 2021-01-26 | 斯基霍克疗法公司 | 用于治疗癌症的化合物 |
| BR112020026637A2 (pt) * | 2018-06-27 | 2021-03-30 | Reborna Biosciences, Inc. | Agente profilático ou terapêutico para atrofia muscular espinhal |
| CR20230007A (es) * | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
-
2021
- 2021-04-08 JP JP2022561080A patent/JP2023520916A/ja active Pending
- 2021-04-08 MX MX2022012678A patent/MX2022012678A/es unknown
- 2021-04-08 EP EP21722078.9A patent/EP4132646A1/en active Pending
- 2021-04-08 US US17/917,729 patent/US20230159496A1/en active Pending
- 2021-04-08 IL IL297137A patent/IL297137A/en unknown
- 2021-04-08 BR BR112022020423A patent/BR112022020423A2/pt unknown
- 2021-04-08 KR KR1020227038394A patent/KR20220167298A/ko active Pending
- 2021-04-08 AU AU2021253587A patent/AU2021253587A1/en active Pending
- 2021-04-08 WO PCT/US2021/026437 patent/WO2021207532A1/en not_active Ceased
- 2021-04-08 US US17/917,734 patent/US20230167093A1/en active Pending
- 2021-04-08 CR CR20220566A patent/CR20220566A/es unknown
- 2021-04-08 TW TW110112826A patent/TWI912305B/zh active
- 2021-04-08 CN CN202180027107.3A patent/CN115551593A/zh active Pending
- 2021-04-08 WO PCT/US2021/026481 patent/WO2021207554A1/en not_active Ceased
- 2021-04-08 CA CA3174353A patent/CA3174353A1/en active Pending
-
2022
- 2022-10-07 CL CL2022002780A patent/CL2022002780A1/es unknown
- 2022-11-04 CO CONC2022/0015925A patent/CO2022015925A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4132646A1 (en) | 2023-02-15 |
| CN115551593A (zh) | 2022-12-30 |
| JP2023520916A (ja) | 2023-05-22 |
| MX2022012678A (es) | 2023-01-11 |
| AU2021253587A1 (en) | 2022-12-01 |
| BR112022020423A2 (pt) | 2022-11-29 |
| CL2022002780A1 (es) | 2023-04-28 |
| TW202208344A (zh) | 2022-03-01 |
| US20230167093A1 (en) | 2023-06-01 |
| CA3174353A1 (en) | 2021-10-14 |
| WO2021207532A1 (en) | 2021-10-14 |
| WO2021207554A1 (en) | 2021-10-14 |
| CO2022015925A2 (es) | 2024-09-09 |
| US20230159496A1 (en) | 2023-05-25 |
| KR20220167298A (ko) | 2022-12-20 |
| TWI912305B (zh) | 2026-01-21 |
| IL297137A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220566A (es) | Compuestos y métodos para modular el corte y empalme | |
| CO2022013827A2 (es) | Compuestos y métodos para modular el empalme | |
| CO2022015926A2 (es) | Compuestos y métodos para modular el empalme | |
| BR112022017089A2 (pt) | Derivados de piridazina para modular o splicing de ácido nucleico | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CO2022008406A2 (es) | Degradadores de irak y usos de los mismos | |
| BR112018006259A2 (pt) | "adjunto compressível com estruturas de suporte intermediárias" | |
| MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| CO2020002959A2 (es) | Moduladores de piruvato quinasas y uso de los mismos | |
| CL2024000821A1 (es) | Composiciones moduladoras de la subunidad beta e de la inhibina (inhbe) y métodos | |
| EA202190520A1 (ru) | Полимерная композиция с фосфонатным антипиреном | |
| CL2022001456A1 (es) | Tiofenocarboxamidas sustituidas y sus derivados | |
| UY39368A (es) | Composiciones para modular el empalme | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| CL2022001594A1 (es) | Tiofenocarboxamidas sustituidas y sus derivados | |
| CL2022001612A1 (es) | Tieniloxazolonas y análogos | |
| ECSP24016785A (es) | Compuestos y métodos para modular splicing | |
| CL2024000632A1 (es) | Compuestos y métodos para modular el empalme | |
| MX2018014783A (es) | Aparato de visualizacion, montaje para modular adaptativamente el contraste de la visualizacion del aparato de visualizacion y metodo para modular adaptativamente el contraste de la visualizacion del aparato de visualizacion. | |
| CO2025017487A2 (es) | Compuestos y métodos para modular el empalme | |
| PY1965505A (es) | Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos | |
| ECSP21062129A (es) | Formulación de herbicida estable de pirazosulfuronetilo |